RUNX2, the master transcription factor for osteogenic differentiation, is overexpressed in several tumor tissues, including pancreatic cancer, breast cancer, ovarian epithelial cancer, prostate cancer, lung cancer, thyroid cancer and in osteosarcoma [14]. Here, RUNX2 is linked to prostate cancer.